

# Richard W Chapman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8494196/publications.pdf>

Version: 2024-02-01

7  
papers

131  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

118  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2022, 916, 174484.	3.5	4
2	Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 152, 106486.	1.9	11
3	An overview of the biology of a long-acting inhaled treprostinil prodrug. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 65, 102002.	2.6	13
4	Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 104-111.	2.6	17
5	Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 95-103.	2.6	32
6	Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation. <i>Drug Research</i> , 2018, 68, 605-614.	1.7	28
7	Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 348-357.	2.5	26